NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness, announced today it has joined the Industry Resource Partnership (IRP) Program of the California Institute for Regenerative Medicine (CIRM), a state agency. The…
Aug 04, 2026, 10:00 ET This milestone marks the next phase of the Company's broader clinical strategy to position TRP-8803 as a precision-controlled treatment platform for high-value disorders with large, undertreated patient populations. The basket study is designed to assess TRP-8803 across multiple…
Kyverna Therapeutics advances Miv-cel for autoimmune diseases, but valuation, launch, and funding risks remain. Click here to read this analysis on KYTX. - Kyverna is advancing Miv-cel, a CAR-T therapy for autoimmune diseases, with positive Phase 2/3 data in SPS and gMG.
Oppenheimer cut Dyne Therapeutics to perform, citing small trial size and data risk for DYN-101 in DM1. - Oppenheimer downgraded Dyne Therapeutics (DYN) to perform from outperform, saying that upcoming data for DYN-101 (zeleciment basivarsen, or z-basivarsen), its candidate for myotonic dystrophy…
Octane Biotech Inc. (“Octane”) and Currus Biologics (“Currus”), an Australian biotech developing the BEAT, a proprietary, universal, bispecific antibody platform to unlock CAR T-cell therapy for solid... Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on…
Edgewise Therapeutics (EWTX) has attracted considerable investor interest in the upcoming phase 3 design for '7500 in hypertrophic cardiomyopathy, representing an opportunity to h... Oops, something went wrong Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says Edgewise…
Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Kate Rausch - Vic President of Corporate Affairs & Investor RelationsPaul Bolno - President, CEO & DirectorChristopher Wright - Chief Medical OfficerKyle Moran - CFO & Principal Accounting OfficerMonika A. Vnuk - Chief Business Officer Hello, and welcome to…
Interested in WAVE Life Sciences Ltd.? Here are five stocks we like better. Third-quarter revenue rose to $13.2 million from $7.6 million, driven mainly by the GSK collaboration, while the net loss widened to $61.9 million as R&D and administrative spending increased.
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a October 27, 2026 8:00 AM EDT Holly Manning - Vice President of Investor Relations & External CommunicationsJohn Evans - CEO & DirectorAmy Simon - Chief Medical OfficerGiuseppe Ciaramella - President Good morning, and…
Good morning. Read on to find out what my colleague was doing in Pennsylvania Dutch country and what the latest dispute between Novo and Lilly is all about. In Pennsylvania Dutch country, one doctor has long been working with biotech…
Companies built on genetic medicines - CRISPR Therapeutics, Intellia, Beam, Sarepta, Ionis, Arrowhead, Kyverna and others - their trials, setbacks and deals.
An article joins this feed when it matches these terms. Each one is also a search of its own.